Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;104(6):426-439.
doi: 10.1002/cyto.b.22144. Epub 2023 Sep 28.

Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry

Jesse M Tettero  1   2 , Naveen Dakappagari  3 , Maaike E Heidinga  1   2 , Yvonne Oussoren-Brockhoff  1   2 , Diana Hanekamp  1   2   4 , Anil Pahuja  3 , Kerri Burns  3 , Pavinder Kaur  3 , Zeni Alfonso  3 , Vincent H J van der Velden  5 , Jeroen G Te Marvelde  5 , Willemijn Hobo  6 , Jennichjen Slomp  7 , Costa Bachas  1   2 , Angele Kelder  1   2 , Kevin Nguyen  3 , Jacqueline Cloos  1   2
Affiliations
Free article

Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry

Jesse M Tettero et al. Cytometry B Clin Cytom. 2023 Nov.
Free article

Abstract

Background: Measurable residual disease (MRD) assessed by multiparametric flow cytometry (MFC) has gained importance in clinical decision-making for acute myeloid leukemia (AML) patients. However, complying with the recent In Vitro Diagnostic Regulations (IVDR) in Europe and Food and Drug Administration (FDA) guidance in the United States requires rigorous validation prior to their use in investigational clinical trials and diagnostics. Validating AML MRD-MFC assays poses challenges due to the unique underlying disease biology and paucity of patient specimens. In this study, we describe an experimental framework for validation that meets regulatory expectations.

Methods: Our validation efforts focused on evaluating assay accuracy, analytical specificity, analytical and functional sensitivity (limit of blank (LoB), detection (LLoD) and quantitation (LLoQ)), precision, linearity, sample/reagent stability and establishing the assay background frequencies.

Results: Correlation between different MFC methods was highly significant (r = 0.99 for %blasts and r = 0.93 for %LAIPs). The analysis of LAIP specificity accurately discriminated from negative control cells. The assay demonstrated a LoB of 0.03, LLoD of 0.04, and LLoQ of 0.1%. Precision experiments yielded highly reproducible results (Coefficient of Variation <20%). Stability experiments demonstrated reliable measurement of samples up to 96 h from collection. Furthermore, the reference range of LAIP frequencies in non-AML patients was below 0.1%, ranging from 0.0% to 0.04%.

Conclusion: In this manuscript, we present the validation of an AML MFC-MRD assay using BM/PB patient specimens, adhering to best practices. Our approach is expected to assist other laboratories in expediting their validation activities to fulfill recent health authority guidelines.

Keywords: assay validation; flow-cytometry; measurable residual disease.

PubMed Disclaimer

References

REFERENCES

    1. Armbruster, D. A., & Pry, T. (2008). Limit of blank, limit of detection and limit of quantitation. The Clinical Biochemist Reviews, 29(Suppl 1), S49-S52.
    1. Buccisano, F., Hourigan, C. S., & Walter, R. B. (2017). The prognostic significance of measurable ("minimal") residual disease in acute myeloid leukemia. Current Hematologic Malignancy Reports, 12(6), 547-556.
    1. Cloos, J., Harris, J. R., Janssen, J. J. W. M., Kelder, A., Huang, F., Sijm, G., Vonk, M., Snel, A. N., Scheick, J. R., Scholten, W. J., Carbaat-Ham, J., Veldhuizen, D., Hanekamp, D., Oussoren-Brockhoff, Y. J. M., Kaspers, G. J. L., Schuurhuis, G. J., Sasser, A. K., & Ossenkoppele, G. (2018). Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia. Journal of Visualized Experiments: JoVE, 133, 56386.
    1. CLSI. (2021). Validation of assays performed by flow cytometry. CLSI guideline H62. Clinical and Laboratory Standards Institute.
    1. Cremers, E. M., Westers, T. M., Alhan, C., Cali, C., Visser-Wisselaar, H. A., Chitu, D. A., van der Velden, V., te Marvelde, J. G., Klein, S. K., Muus, P., Vellenga, E., de Greef, G. E., Legdeur, M. C., Wijermans, P. W., Stevens-Kroef, M. J., Silva-Coelho, P. D., Jansen, J. H., Ossenkoppele, G. J., van de Loosdrecht, A., & A Study on Behalf of the HOVON89 Study Group. (2017). Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica, 102(2), 320-326.

Publication types

LinkOut - more resources